Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Cysteine Hydrochloride Patent Expiration

Cysteine Hydrochloride is used for treating patients needing parenteral nutrition through intravenous administration of a diluted cysteine hydrochloride solution. It was first introduced by Hospira Inc in its drug Cysteine Hydrochloride on Oct 22, 1986. Other drugs containing Cysteine Hydrochloride are Elcys, Nouress. 5 different companies have introduced drugs containing Cysteine Hydrochloride.


Cysteine Hydrochloride Patents

Given below is the list of patents protecting Cysteine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Nouress US10493051 Cysteine composition and injection Mar 15, 2039 Baxter Hlthcare Corp
Nouress US10543186 Cysteine composition and injection Mar 15, 2039 Baxter Hlthcare Corp
Nouress US10702490 Cysteine composition and injection Mar 15, 2039 Baxter Hlthcare Corp
Nouress US11045438 Cysteine composition and injection Mar 15, 2039 Baxter Hlthcare Corp
Nouress US11510941 Stable, highly pure L-cysteine compositions for injection and methods of use Mar 02, 2039 Baxter Hlthcare Corp
Elcys US10478453 Stable, highly pure L-cysteine compositions for injection and methods of use Jan 15, 2039 Exela Pharma
Elcys US10583155 Stable, highly pure L-cysteine compositions for injection and methods of use Jan 15, 2039 Exela Pharma
Elcys US10653719 Stable, highly pure L-cysteine compositions for injection and methods of use Jan 15, 2039 Exela Pharma
Elcys US10905713 Stable, highly pure L-cysteine compositions for injection and methods of use Jan 15, 2039 Exela Pharma
Elcys US10905714 Stable, highly pure L-cysteine compositions for injection and methods of use Jan 15, 2039 Exela Pharma
Elcys US10912795 Stable, highly pure L-cysteine compositions for injection and methods of use Jan 15, 2039 Exela Pharma
Elcys US10918662 Stable, highly pure L-cysteine compositions for injection and methods of use Jan 15, 2039 Exela Pharma
Elcys US10933089 Stable, highly pure L-cysteine compositions for injection and methods of use Jan 15, 2039 Exela Pharma
Elcys US11510941 Stable, highly pure L-cysteine compositions for injection and methods of use Jan 15, 2039 Exela Pharma
Elcys US11510942 Stable, highly pure L-cysteine compositions for injection and methods of use Jan 15, 2039 Exela Pharma
Elcys US11642370 Stable, highly pure L-cysteine compositions for injection and methods of use Jan 15, 2039 Exela Pharma
Elcys US11648262 Stable, highly pure L-cysteine compositions for injection and methods of use Jan 15, 2039 Exela Pharma
Elcys US11679125 Stable, highly pure L-cysteine compositions for injection and methods of use Jan 15, 2039 Exela Pharma
Elcys US11684636 Stable, highly pure l-cysteine compositions for injection and methods of use Jan 15, 2039 Exela Pharma
Elcys US11826383 Stable, highly pure L-cysteine compositions for injection and methods of use Jan 15, 2039 Exela Pharma
Elcys US11969439 Stable, highly pure L-cysteine compositions for injection and methods of use Jan 15, 2039 Exela Pharma
Nouress US10478453 Stable, highly pure L-cysteine compositions for injection and methods of use Jan 15, 2039 Baxter Hlthcare Corp
Nouress US10583155 Stable, highly pure L-cysteine compositions for injection and methods of use Jan 15, 2039 Baxter Hlthcare Corp
Nouress US10653719 Stable, highly pure L-cysteine compositions for injection and methods of use Jan 15, 2039 Baxter Hlthcare Corp
Nouress US10905713 Stable, highly pure L-cysteine compositions for injection and methods of use Jan 15, 2039 Baxter Hlthcare Corp
Nouress US10905714 Stable, highly pure L-cysteine compositions for injection and methods of use Jan 15, 2039 Baxter Hlthcare Corp
Nouress US10912795 Stable, highly pure L-cysteine compositions for injection and methods of use Jan 15, 2039 Baxter Hlthcare Corp
Nouress US10918662 Stable, highly pure L-cysteine compositions for injection and methods of use Jan 15, 2039 Baxter Hlthcare Corp
Nouress US10933089 Stable, highly pure L-cysteine compositions for injection and methods of use Jan 15, 2039 Baxter Hlthcare Corp
Nouress US11510942 Stable, highly pure L-cysteine compositions for injection and methods of use Jan 15, 2039 Baxter Hlthcare Corp
Nouress US11642370 Stable, highly pure L-cysteine compositions for injection and methods of use Jan 15, 2039 Baxter Hlthcare Corp
Nouress US11648262 Stable, highly pure L-cysteine compositions for injection and methods of use Jan 15, 2039 Baxter Hlthcare Corp
Nouress US11679125 Stable, highly pure L-cysteine compositions for injection and methods of use Jan 15, 2039 Baxter Hlthcare Corp
Nouress US11684636 Stable, highly pure l-cysteine compositions for injection and methods of use Jan 15, 2039 Baxter Hlthcare Corp
Nouress US11826383 Stable, highly pure L-cysteine compositions for injection and methods of use Jan 15, 2039 Baxter Hlthcare Corp



Cysteine Hydrochloride's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Cysteine Hydrochloride Generic API Manufacturers

Several generic applications have been filed for Cysteine Hydrochloride. The first generic version for Cysteine Hydrochloride was by Dr Reddys Laboratories Sa and was approved on Apr 8, 2022. And the latest generic version is by Hikma Pharmaceuticals Usa Inc and was approved on Jan 26, 2023.

Given below is the list of companies who have filed for Cysteine Hydrochloride generic, along with the locations of their manufacturing plants worldwide.


1. DR REDDYS LABS SA

Dr Reddys Laboratories Sa has filed for 1 generic for Cysteine Hydrochloride. Given below are the details of the strengths of this generic introduced by Dr Reddys Labs Sa.

Strength Dosage Form Availability Application Pathway TE code Launch Date
500MG/10ML (50MG/ML)

solution Discontinued INTRAVENOUS N/A Apr 8, 2022





2. HIKMA

Hikma Pharmaceuticals Usa Inc has filed for 1 generic for Cysteine Hydrochloride. Given below are the details of the strengths of this generic introduced by Hikma.

Strength Dosage Form Availability Application Pathway TE code Launch Date
7.25%

injectable Discontinued INJECTION N/A Jan 26, 2023


Manufacturing Plant Locations
New

Hikma's manufacturing plants are situated in 3 countries - United States, Portugal, Jordan. Given below are the details of these plant locations as well as the firm names of Hikma as present at those locations.

Country City Firm Name
United States
Eatontown Hikma Pharmaceuticals USA, Inc.
Cherry Hill Hikma Pharmaceuticals USA Inc.
Dayton Hikma Injectables USA Inc
Carlsbad Hikma Cali Inc. DBA Leucadia Pharmaceuticals
Portugal
Terrugem Snt Hikma Farmaceutica, (Portugal) S.A.
Jordan
Amman Hikma Pharmaceuticals LLC